查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1596216

呼吸道疾病疫苗市場：依感染疾病、類型、年齡層別分類 - 全球預測 2025-2030 年

Respiratory Disease Vaccine Market by Infection (Influenza Virus, Pertussis, Streptococcus Pneumoniae), Type (Bacterial Vaccine, Combination Vaccine, Viral Vaccine), Age Group - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年呼吸道疾病疫苗市值為234.2億美元，預計2024年將達到247.8億美元，複合年成長率為5.87%，預計到2030年將達到349.3億美元。

呼吸道疾病疫苗市場的範圍和定義包括用於預防影響呼吸系統的疾病的疫苗的開發、生產和分銷，例如流感、COVID-19和呼吸道融合細胞病毒（RSV）。世界上持續存在的呼吸道疾病負擔凸顯了對這些疫苗的需求，這些疾病造成了顯著的發病率和死亡率，並影響了公共衛生系統和經濟。呼吸道疫苗在季節性疫苗宣傳活動和集體爆發應對措施中具有廣泛的應用範圍，從兒童到成人。最終用途範圍主要針對醫院和診所等醫療機構，但也擴展到政府免疫計畫和私人消費者。

主要市場統計
基準年[2023] 234.2億美元
預測年份 [2024] 247.8億美元
預測年份 [2030] 349.3億美元
複合年成長率（%） 5.87%

市場成長的推動因素包括預防保健意識的增強、疫苗技術的進步以及政府對疫苗接種計劃的支持。持續的COVID-19大流行進一步加速了該領域的投資和研究，為mRNA疫苗和鼻腔給藥系統等創新提供了潛在機會。公司應專注於利用合作研究夥伴關係和資料分析來制定有效的市場滲透策略。然而，市場開拓面臨開發成本高、監管障礙、人群遠離疫苗等挑戰。維持供應鏈完整性以及處理儲存和分銷物流也是主要限制因素。

為了利用這些機會，公司可以投資於開發提供更廣泛保護的通用疫苗以及整合人工智慧進行預測模型以最佳化疫苗功效和分配等領域。低溫運輸物流的創新以及用於疫苗生產的植物和宿主載體系統的探索是未來成長的研究領域。該市場本質上是動態的、多學科的，涵蓋生物技術、醫學和資料分析，需要統一的方法才能取得成功。有效滿足不斷成長的需求、技術進步和監管合規性的公司將獲得策略定位，以便在快速發展的呼吸道疾病疫苗市場中取得成功。

市場動態：快速發展的呼吸道疾病疫苗市場的關鍵市場洞察

供需的動態交互作用正在改變呼吸道疾病疫苗市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 呼吸道疾病盛行率增加
    • 臨床試驗和疫苗開發正在進行中
    • 政府支持呼吸健康的舉措
  • 市場限制因素
    • 醫療基礎設施不足和意識有限
  • 市場機會
    • 主要企業研發費用增加
    • 透過轉售合作夥伴關係增加疫苗的供應
  • 市場挑戰
    • 消費者對呼吸道疾病疫苗接種的信任與信心

波特五力：駕馭呼吸道疾病疫苗市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解呼吸道疾病疫苗市場的外部影響

外部宏觀環境因素對呼吸道疾病疫苗市場的表現動態起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解呼吸道疾病疫苗市場的競爭格局

對呼吸系統疾病疫苗市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣呼吸道疾病疫苗市場供應商的績效評估

FPNV 定位矩陣是評估呼吸道疾病疫苗市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃呼吸道疾病疫苗市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對呼吸道疾病疫苗市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 呼吸道疾病盛行率增加
      • 臨床試驗和疫苗開發正在進行中
      • 政府支持呼吸健康的舉措
    • 抑制因素
      • 配送基礎設施薄弱且意識缺乏
    • 機會
      • 主要企業研發費用增加
      • 透過轉售合作增加疫苗的供應
    • 任務
      • 消費者對呼吸道疾病疫苗的信任與信心
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 呼吸道疾病疫苗市場受感染狀況

  • 流感病毒
  • 百日咳
  • 肺炎球菌
  • 結核

第7章呼吸系統疾病疫苗市場：依類型

  • 細菌疫苗
  • 聯合疫苗
  • 病毒疫苗

第8章呼吸道疾病疫苗市場：依年齡層別

  • 青少年疫苗接種
  • 成人疫苗接種
  • 嬰兒疫苗接種

第9章美洲呼吸道疾病疫苗市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太呼吸道疾病疫苗市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲呼吸道疾病疫苗市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Astrazeneca PLC
  • Bavarian Nordic A/S
  • Bharat Biotech International Ltd.
  • CanSino Biologics Inc.
  • Emergent BioSolutions, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Seqirus USA Inc.
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • Vaxine Pty Ltd.
Product Code: MRR-035AB9C0DAB0

The Respiratory Disease Vaccine Market was valued at USD 23.42 billion in 2023, expected to reach USD 24.78 billion in 2024, and is projected to grow at a CAGR of 5.87%, to USD 34.93 billion by 2030.

The scope and definition of the respiratory disease vaccine market encompass the development, production, and distribution of vaccines aimed at preventing diseases affecting the respiratory system, such as influenza, COVID-19, and respiratory syncytial virus (RSV). The necessity of these vaccines is underscored by the persistent global burden of respiratory illnesses, which cause significant morbidity and mortality, impacting public health systems and economies. The application of respiratory vaccines is robust, involving both pediatric and adult populations, and spans both seasonal vaccination campaigns and outbreak response initiatives. End-use scope primarily covers healthcare institutions, including hospitals and clinics, and extends to government vaccination programs and individual consumers.

KEY MARKET STATISTICS
Base Year [2023] USD 23.42 billion
Estimated Year [2024] USD 24.78 billion
Forecast Year [2030] USD 34.93 billion
CAGR (%) 5.87%

Market growth is driven by factors such as increasing awareness about preventive healthcare, advances in vaccine technologies, and governmental support for vaccination programs. The ongoing COVID-19 pandemic has further accelerated investments and research in this sector, providing potential opportunities for innovations like mRNA vaccines and intranasal delivery systems. Companies should focus on collaborative research partnerships and leveraging data analytics for effective market penetration strategies. However, market growth faces challenges like high development costs, regulatory hurdles, and vaccine hesitancy among populations. Maintaining supply chain integrity and addressing storage and distribution logistics also pose significant limitations.

To capitalize on these opportunities, businesses can invest in areas like the development of universal vaccines that offer broader protection and the integration of artificial intelligence for predictive modeling in vaccine efficacy and distribution optimization. Innovation in cold chain logistics and exploring plant-based and host-vector systems for vaccine production are promising research areas for future growth. The market is dynamic, with a multidisciplinary nature that spans biotechnology, medical science, and data analytics, requiring a harmonized approach for success. Companies that effectively address the rising demand, technological advancements, and regulatory compliance will be strategically positioned to thrive in the rapidly evolving respiratory disease vaccine market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Respiratory Disease Vaccine Market

The Respiratory Disease Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of respiratory disorders
    • Clinical trials and vaccines developments in pipeline
    • Government initiatives supporting respiratory health
  • Market Restraints
    • Lack of inadequate delivery infrastructure & limited awareness
  • Market Opportunities
    • Increasing R&D expenditure by leading companies
    • Increase vaccine availability through reselling collaborations
  • Market Challenges
    • Consumer trust & confidence in respiratory disease vaccination

Porter's Five Forces: A Strategic Tool for Navigating the Respiratory Disease Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Respiratory Disease Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Respiratory Disease Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Respiratory Disease Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Respiratory Disease Vaccine Market

A detailed market share analysis in the Respiratory Disease Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Respiratory Disease Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Respiratory Disease Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Respiratory Disease Vaccine Market

A strategic analysis of the Respiratory Disease Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Respiratory Disease Vaccine Market, highlighting leading vendors and their innovative profiles. These include Astrazeneca PLC, Bavarian Nordic A/S, Bharat Biotech International Ltd., CanSino Biologics Inc., Emergent BioSolutions, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Moderna, Inc., Pfizer Inc., Sanofi S.A., Seqirus USA Inc., Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., and Vaxine Pty Ltd..

Market Segmentation & Coverage

This research report categorizes the Respiratory Disease Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Infection, market is studied across Influenza Virus, Pertussis, Streptococcus Pneumoniae, and Tuberculosis.
  • Based on Type, market is studied across Bacterial Vaccine, Combination Vaccine, and Viral Vaccine.
  • Based on Age Group, market is studied across Adolescent Vaccination, Adult Vaccination, and Infant Vaccination.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of respiratory disorders
      • 5.1.1.2. Clinical trials and vaccines developments in pipeline
      • 5.1.1.3. Government initiatives supporting respiratory health
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of inadequate delivery infrastructure & limited awareness
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing R&D expenditure by leading companies
      • 5.1.3.2. Increase vaccine availability through reselling collaborations
    • 5.1.4. Challenges
      • 5.1.4.1. Consumer trust & confidence in respiratory disease vaccination
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Respiratory Disease Vaccine Market, by Infection

  • 6.1. Introduction
  • 6.2. Influenza Virus
  • 6.3. Pertussis
  • 6.4. Streptococcus Pneumoniae
  • 6.5. Tuberculosis

7. Respiratory Disease Vaccine Market, by Type

  • 7.1. Introduction
  • 7.2. Bacterial Vaccine
  • 7.3. Combination Vaccine
  • 7.4. Viral Vaccine

8. Respiratory Disease Vaccine Market, by Age Group

  • 8.1. Introduction
  • 8.2. Adolescent Vaccination
  • 8.3. Adult Vaccination
  • 8.4. Infant Vaccination

9. Americas Respiratory Disease Vaccine Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Respiratory Disease Vaccine Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Respiratory Disease Vaccine Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Astrazeneca PLC
  • 2. Bavarian Nordic A/S
  • 3. Bharat Biotech International Ltd.
  • 4. CanSino Biologics Inc.
  • 5. Emergent BioSolutions, Inc.
  • 6. GlaxoSmithKline PLC
  • 7. Johnson & Johnson Services, Inc.
  • 8. Merck & Co., Inc.
  • 9. Moderna, Inc.
  • 10. Pfizer Inc.
  • 11. Sanofi S.A.
  • 12. Seqirus USA Inc.
  • 13. Serum Institute of India Pvt. Ltd.
  • 14. Sinovac Biotech Ltd.
  • 15. Vaxine Pty Ltd.

LIST OF FIGURES

  • FIGURE 1. RESPIRATORY DISEASE VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. RESPIRATORY DISEASE VACCINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. RESPIRATORY DISEASE VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. RESPIRATORY DISEASE VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. RESPIRATORY DISEASE VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. RESPIRATORY DISEASE VACCINE MARKET DYNAMICS
  • TABLE 7. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFLUENZA VIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PERTUSSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY STREPTOCOCCUS PNEUMONIAE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY BACTERIAL VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COMBINATION VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VIRAL VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADOLESCENT VACCINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT VACCINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFANT VACCINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 147. RESPIRATORY DISEASE VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. RESPIRATORY DISEASE VACCINE MARKET, FPNV POSITIONING MATRIX, 2023